Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer's Disease: Implications for the Treatment
- PMID: 24082824
- PMCID: PMC3637679
- DOI: 10.2174/1389202911314020007
Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer's Disease: Implications for the Treatment
Abstract
Late-onset Alzheimer's disease (LOAD) is the most common form of dementia in the elderly. LOAD has a complex and largely unknown etiology with strong genetic determinants. Genetics of LOAD is known to involve several genetic risk factors among which the Apolipoprotein E (APOE) gene seems to be the major recognized genetic determinant. Recent efforts have been made to identify other genetic factors involved in the pathophysiology of LOAD such as genes associated with a deficit of neurotrophic factors in the AD brain. Genetic variations of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), and transforming-growth-factor-β1 (TGF-β1) are known to increase the risk to develop LOAD and have also been related to depression susceptibility in LOAD. Transforming-Growth-Factor-β1 (TGF-β1) is a neurotrophic factor that exerts neuroprotective effects against ß-amyloid-induced neurodegeneration. Recent evidence suggests that a specific impairment in the signaling of TGF-β is an early event in the pathogenesis of AD. TGF-β1 protein levels are predominantly under genetic control, and the TGF-β1 gene, located on chromosome 19q13.1-3, con-tains several single nucleotide polymorphisms (SNPs) upstream and in the transcript region, such as the SNP at codon +10 (T/C) and +25 (G/C), which is known to influence the level of expression of TGF-β1. In the present review, we summarize the current literature on genetic risk factors for LOAD, focusing on the role of the TGF-β1 gene, finally discussing the possible implications of these genetic studies for the selection of patients eligible for neuroprotective strategies in AD.
Keywords: Alzheimer’s disease; Depression; Drugs; Genetic polymorphism; Risk factor; Transforming-growth-factor-β1..
Similar articles
-
The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression.Eur Neuropsychopharmacol. 2012 Apr;22(4):281-9. doi: 10.1016/j.euroneuro.2011.08.006. Epub 2011 Sep 15. Eur Neuropsychopharmacol. 2012. PMID: 21924590
-
Neurobiological links between depression and AD: The role of TGF-β1 signaling as a new pharmacological target.Pharmacol Res. 2018 Apr;130:374-384. doi: 10.1016/j.phrs.2018.02.007. Epub 2018 Feb 10. Pharmacol Res. 2018. PMID: 29438781 Review.
-
Association between polymorphisms in transforming growth factor-β1 and sporadic Alzheimer's disease in a Chinese population.Int J Neurosci. 2016 Nov;126(11):979-84. doi: 10.3109/00207454.2015.1088849. Epub 2015 Sep 22. Int J Neurosci. 2016. PMID: 26327336
-
Association of a polymorphism of the transforming growth factor-beta1 gene with cerebral amyloid angiopathy.J Neurol Neurosurg Psychiatry. 2005 May;76(5):696-9. doi: 10.1136/jnnp.2003.034454. J Neurol Neurosurg Psychiatry. 2005. PMID: 15834029 Free PMC article.
-
TGF-β1 pathway as a new target for neuroprotection in Alzheimer's disease.CNS Neurosci Ther. 2011 Aug;17(4):237-49. doi: 10.1111/j.1755-5949.2009.00115.x. Epub 2009 Nov 19. CNS Neurosci Ther. 2011. PMID: 19925479 Free PMC article. Review.
Cited by
-
Specific exercise patterns generate an epigenetic molecular memory window that drives long-term memory formation and identifies ACVR1C as a bidirectional regulator of memory in mice.Nat Commun. 2024 May 7;15(1):3836. doi: 10.1038/s41467-024-47996-w. Nat Commun. 2024. PMID: 38714691 Free PMC article.
-
Serum calreticulin is a negative biomarker in patients with Alzheimer's disease.Int J Mol Sci. 2014 Nov 25;15(12):21740-53. doi: 10.3390/ijms151221740. Int J Mol Sci. 2014. PMID: 25429433 Free PMC article.
-
TGF-β1 protection against Aβ1-42-induced neuroinflammation and neurodegeneration in rats.Int J Mol Sci. 2014 Dec 1;15(12):22092-108. doi: 10.3390/ijms151222092. Int J Mol Sci. 2014. PMID: 25470026 Free PMC article.
-
Cellular Localization and Distribution of TGF-β1, GDNF and PDGF-BB in the Adult Primate Central Nervous System.Neurochem Res. 2023 Aug;48(8):2406-2423. doi: 10.1007/s11064-023-03909-9. Epub 2023 Mar 28. Neurochem Res. 2023. PMID: 36976393
-
TGF-β Signaling: A Therapeutic Target to Reinstate Regenerative Plasticity in Vascular Dementia?Aging Dis. 2020 Jul 23;11(4):828-850. doi: 10.14336/AD.2020.0222. eCollection 2020 Jul. Aging Dis. 2020. PMID: 32765949 Free PMC article. Review.
References
-
- Hardy J. The amyloid hypothesis for Alzheimer's disease a critical reappraisal. J. Neurochem. 2009;110(4):1129–1134. - PubMed
-
- Ballard C, Day S, Sharp S, Wing G, Sorensen S. Neuropsychiatric symptoms in dementia importance and treatment considerations. Int. Rev. Psychiatry . 2008;20(4):396–404. - PubMed
-
- Fang Y, Zhang L, Zeng Z, Lian Y, Jia Y, Zhu H, Xu Y. Promoter polymorphisms of serpine1 are associated with the antidepressant response to depression in Alzheimer's disease. Neurosci. Lett. 2012;516(2):217–220. - PubMed
-
- Combarros O, Alvarez-Arcaya A, Oterino A, Berciano J, Delgado-Rodríguez M, Peña N, Fernández-Viadero C, Pérez-López LJ, Setién S, Carvajal A. Polymorphisms in the presenilin 1 and presenilin 2 genes and risk for sporadic alzheimer’s disease. J. Neurol. Sci. 1999;171(2):88–91. - PubMed
-
- Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, Mazzoleni G, Merlin M, Giovagnoli AR, Prioni S, Erbetta A, Falcone CM, Gobbi M, Colombo L, Bastone A, Beeg M, Manzoni C, Francescucci B, Spagnoli A, Cantù L, Del Favero E, Levy E, Salmona M, Tagliavini F. A recessive mutation in the APP gene with dominant- negative effect on amyloidogenesis. Science . 2009;323(5920):1473–1477. - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous